Context: Erythrocytosis is a dose-limiting adverse effect of testosterone therapy, especially in older men.
I
ncrease in hematocrit is a predictable effect of testosterone therapy (1) (2) (3) (4) (5) (6) . Erythrocytosis is the most frequently reported adverse event in testosterone trials (2) . Anecdotally, older men appear more sensitive to the erythropoietic effects of testosterone than young men (7) (8) (9) (10) , although a head-to-head comparison of the effects of testosterone therapy on hematocrit in young and older men has not been conducted. In a recent comparison of the responsiveness of young and older men to graded doses of testosterone, a greater number of older men had to be discontinued from the trial because of an increase in hematocrit above 54% (11, 12) ; in contrast, none of the young men experienced increase in hematocrit above 54% even at a 600-mg weekly dose of testosterone enanthate. Therefore, we conducted a secondary analysis of hemoglobin and hematocrit data from the testosterone dose-response study to determine whether older men were more sensitive to the erythropoietic effects of testosterone than young men.
The Endocrine Society Guideline on Androgen Deficiency Syndromes in Men recommended hematocrit monitoring 3 months after initiation of testosterone therapy and annually thereafter (1) . However, in a number of participants in our doseresponse study, the hematocrit continued to rise after 12 wk. Therefore, a second objective of our analyses was to evaluate the time course of hematocrit change after testosterone therapy.
The mechanisms by which testosterone stimulates erythropoiesis are poorly understood. It has been postulated that testosterone induces erythrocytosis by stimulating erythropoietin production (13, 14) . The effects of testosterone on erythropoietin levels have been inconsistent in previous studies (15, 16) . Testosterone also acts directly on the bone marrow, increasing the number of erythropoietin-responsive cells (5, 17) . The soluble transferrin receptor (sTfR), involved in the intracellular transport of iron, correlates directly with the degree of erythropoietic activity in the bone marrow (18) , and sTfR levels have been used as a marker of erythropoietic activity (18, 19) . We determined whether the increases in hematocrit during testosterone therapy are associated with dose-related increases in erythropoietin and sTfR levels. We also assessed whether differences in hemoglobin and hematocrit responses in older and younger men receiving graded doses of testosterone enanthate could be explained by age-related differences in the changes in erythropoietin and sTfR.
Subjects and Methods
The hemoglobin and hematocrit responses to graded doses of testosterone enanthate were compared from a previous testosterone dose-response study in 61 young men, aged 18 -35 yr (11, 12) , and 60 older men, aged 60 -75 yr (11) ; the design and main findings of this study have been reported (11, 12) . This randomized, double-blinded study consisted of a 4-wk control period, a 20-wk treatment period, and a 16-wk recovery period. The study protocols were approved by the institutional review boards of Charles Drew University and Harbor-UCLA Research and Education Institute. Participants provided written, informed consent.
Exclusion criteria included a history of prostate cancer, prostatespecific antigen more than 4 ng/ml, a score of more than 7 on American Urologic Association prostatic symptom questionnaire, hematocrit greater than 48%, severe sleep apnea, diabetes mellitus, congestive heart failure, use of androgens, or participation in moderate to intense exercise training.
Participants were randomized to one of five groups to receive monthly injections of a GnRH agonist (leuprolide depot 7.5 mg; TAP, North Chicago, IL) to suppress endogenous gonadotropin production and weekly im injections of 25, 50, 125, 300, or 600 mg testosterone enanthate (Delatestryl; Savient, Iselin, NJ).
The Data and Safety Monitoring Board stopped the 600-mg testosterone enanthate dose group in December 2002 due to the number of adverse events in older men in this dose group. Subsequently, participants were randomized to the 25-, 50-, 125-, or 300-mg group.
Outcome measures
Total testosterone was measured by a RIA that has been validated against liquid chromatography tandem mass spectrometry (11) . Free testosterone was measured by an equilibrium dialysis procedure that has a sensitivity of 0.22 pg/ml, and intra-and interassay coefficients of variation (CV) of 4.2 and 12.3%, respectively (20) . Serum SHBG levels were measured by an immunofluorometric assay that has a sensitivity of 6.25 nmol/liter.
Quantikine ELISA (R&D Systems, Inc., Minneapolis, MN) was used to measure erythropoietin. This double-antibody sandwich method uses recombinant human erythropoietin as standard. The assay had a sensitivity of 0.6 mIU/ml with intra-and interassay CV of 2.1-3.1% and 3.7-4.2%, respectively. sTfR concentrations were measured using a Quantikine ELISA (R&D Systems) based on the double-antibody sandwich method with a sensitivity 0.5 nmol/liter. The intra-and interassay CV are 0.3-2.5% and 0.7-3.8%, respectively.
Statistical analyses
All outcome variables were evaluated for distribution and homogeneity of variance; variables that did not meet the assumptions of homogeneity of variance or normal distribution were log-transformed. ANOVA was used to evaluate differences across dose groups stratified by age, younger vs. older. Changes within groups from baseline to treatment were evaluated with paired t tests. For determining statistical significance, ␣ was set at 0.05. Data are presented as mean Ϯ SEM or mean percent change from baseline Ϯ SEM.
Results

Subjects
The characteristics of the participants have been described (11, 12) . Fifty-two young men of the 61 randomized and 52 older men of the 60 randomized completed the study. The reasons for treatment discontinuation have been described (11) . Only subjects in whom hemoglobin, hematocrit, and testosterone data were available through wk 12 were included in the analysis of erythropoietin and sTfR.
Compliance
General Clinical Research Center staff administered all injections to assure compliance. All participants received all scheduled GnRH agonist injections. One participant in the 125-mg testosterone enanthate group missed one testosterone enanthate injection with an overall compliance rate of more than 99%.
Baseline characteristics
Baseline total and free testosterone, SHBG, hemoglobin, hematocrit, erythropoietin, or sTfR values did not differ among dose groups at baseline in either the young or older male group. However, older men had lower total and free testosterone and hemoglobin concentrations and higher SHBG and higher body weight and body mass index than young men, as reported (11).
Hormones
As reported (11), both total and free testosterone increased with testosterone enanthate dose and were significantly higher in older men than young men in the 125-, 300-, and 600-mg dose groups (P Ͻ 0.05).
Hemoglobin and hematocrit (Fig. 1)
Hemoglobin and hematocrit changed in a linear, dose-dependent fashion in both young and older men (P Ͻ 0.0001). Total and free testosterone concentrations during treatment were correlated significantly with changes in hemoglobin (total testosterone r ϭ 0.57, P Ͻ 0.0001; free testosterone r ϭ 0.52, P Ͻ 0.0001) and hematocrit (total testosterone r ϭ 0.63, P Ͻ 0.0001; free testosterone r ϭ 0.59, P Ͻ 0.0001).
Because older men had higher total and free testosterone levels than younger men, we assessed whether incremental increases in hemoglobin and hematocrit were greater in older men after adjusting for total and free testosterone levels. This analysis revealed that even after adjusting for total and free testosterone levels, the percent change in hemoglobin and hematocrit was significantly different in older and young men (P Յ 0.0001 for each).
Changes in hematocrit also were correlated with treatment estradiol concentrations (Pearson correlation coefficient ϭ 0.48, P ϭ 0.0003, for young men, and ϭ 0.68, P ϭ 0.0001, for older men). However, estradiol concentrations were highly correlated with total testosterone concentrations ( for young men ϭ 0.65, P Ͻ 0.0001; for older men ϭ 0.91, P Ͻ 0.0001). After adjusting for testosterone levels, the changes in hematocrit and hemoglobin were not significantly correlated with estradiol concentrations.
Time course of hemoglobin and hematocrit change (Fig. 1) Hemoglobin and hematocrit started to increase within 1 month after treatment initiation and continued to increase in many subjects after wk 12. A majority of treatment discontinuations due to erythrocytosis occurred after wk 12. On average, the hematocrit in older men peaked later and at a higher level than younger men. Thirty-eight percent of older men in the 25-mg group, 58% in the 50-mg group, 75% in the 125-mg group, 85% in the 300-mg group, and 83% in the 600-mg group, respectively, achieved peak hematocrit levels after wk 12. Similarly, 42% of young men in the 125-mg group, 70% in the 300-mg group, and 85% in the 600-mg group achieved peak hematocrit levels after wk 12.
Erythropoietin levels
Changes in erythropoietin levels did not differ among the five dose groups in either young or older men (ANOVA, young men P ϭ 0.71, older men P ϭ 0.64, Fig. 2A ). Serum erythropoietin levels were not significantly different between young and older men. The percent change in erythropoietin levels was also not significantly different between young and older men. There was no significant difference in percent change from baseline in erythropoietin levels across dose groups in either young or older men.
Total and free testosterone levels did not significantly correlate with erythropoietin levels at baseline in either young or older men. Also, total and free testosterone levels did not correlate significantly with changes in erythropoietin levels in young or older men (Fig. 2C) .
sTfR levels sTfR levels were not significantly different between young and older men at baseline. The changes in sTfR levels did not differ among the five dose groups either in young or in older men (ANOVA, young men P ϭ 0.08, older men P ϭ 0.054, Fig. 2B ). The percent change in sTfR levels during treatment was not significantly different between the young and older men. There was Overall ANOVA did not reveal an age or dose effect. C, Changes in serum erythropoietin levels in young (E with dashed line) and older men (f with solid line) are plotted against serum total testosterone (left panel) and free testosterone (right panel) levels during testosterone treatment. There was no significant correlation between total or free testosterone and change in erythropoietin levels in either young or older men. There was no age effect on the relationship between percent change in erythropoietin levels and testosterone levels. D, Changes in serum sTfR levels in young (E with dashed line) and older men (f with solid line) are plotted against serum total testosterone (left panel) and free testosterone (right panel) levels during testosterone treatment. There was no significant correlation between total or free testosterone during treatment and change in StFR levels in either young or older men. There was no age effect on the relationship between percent change in sFtR levels and testosterone levels. T, Testosterone; TE, testosterone enanthate. no significant difference in percent change from baseline in serum sTfR levels across testosterone dose groups in either younger or older men (Fig. 2B) . Testosterone dose or serum total and free testosterone levels were not significantly correlated with changes in sTfR levels (Fig. 2D) .
Discussion
Despite the strong association of testosterone dose and erythrocytosis, we found no dose-dependent effect of testosterone enanthate on erythropoietin or sTfR levels. Testosterone-associated increase in hemoglobin was not accompanied by a significant increase in erythropoietin or sTfR levels. Thus, the greater increase in hematocrit and hemoglobin observed in older men during testosterone therapy is not explained by the changes in erythropoietin and sTfR levels.
The stimulatory effects of testosterone on erythropoiesis are widely recognized (1, 2, 5, 17) . Androgens have been used to treat anemia of chronic renal failure (21) . Erythrocytosis is the most frequent dose-limiting adverse event associated with testosterone therapy (1, 2) . Both testosterone dose and mode of delivery affect the magnitude of hematocrit elevation (1) (2) (3) 12) . Testosterone ester injections have been reported to be associated with a higher risk of erythrocytosis than oral or transdermal testosterone (3, 7, 8, 22) ; however, it is unclear whether the higher frequency of erythrocytosis observed with injectable testosterone esters is due to the higher dose of testosterone delivered by the injections or the higher peaks of testosterone levels.
The role of erythropoietin in mediating testosterone-induced increase in hematocrit has remained unclear. Men and women have significant differences in testosterone as well as hematocrit levels; however, their erythropoietin levels are not significantly different (23) . sTfR levels are also comparable in men and women (19) . Dickerman et al. (15) observed that a majority of subjects with androgen-induced erythrocytosis had low rather than high erythropoietin levels. Earlier studies (24, 25) of androgen therapy in aplastic anemia showed that androgens are effective despite markedly elevated levels of erythropoietin before therapy. Studies in patients with kidney disease also have found no erythropoietin response to androgen therapy (26) . These data suggest that the androgen effects on erythropoiesis may be mediated through mechanisms other than erythropoietin and sTfR levels.
It is possible that testosterone stimulates erythropoiesis through a direct effect on the bone marrow hematopoietic stem cells (15, 19) ; these direct erythropoietic effects involve IGF-I induction (19) through androgen receptor-mediated mechanisms (27) . Androgens have been shown to stimulate erythroid colony-forming units in the bone marrow (13, 28) and promote their differentiation into erythropoietin-responsive cells. Testosterone enhances intestinal iron absorption, iron incorporation in red blood cells, and hemoglobin synthesis (17) . Androgentreated men with end-stage renal disease have been reported to have longer erythrocyte survival and higher levels of 2,3-diphosphoglycerate than controls (5, 29, 30 ). The molecular mechanisms by which testosterone regulates erythropoiesis and that account for the age-related differences in androgen responsiveness need further investigation.
Our data confirm clinical experience that the frequency of erythrocytosis is greater in older men receiving testosterone therapy than in young men (11) . The greater increments in hematocrit in older men may in part be due to the higher testosterone levels achieved in older men, but the age effect persisted even after adjusting for the higher total and free testosterone levels in older men. The mechanisms of this age-related difference in the erythropoietic response to testosterone are unknown. It is possible that aging is associated with increased production of an erythropoietic inhibitor and that testosterone inhibits the production of this inhibitor.
These data have implications for testosterone therapy of androgen deficiency syndromes in men. The Endocrine Society Guideline for Testosterone Therapy recommended hematocrit monitoring at baseline, 3 months, and annually thereafter (1) . Our data show that hematocrits continue to increase in some men even after 3 months; additional hematocrit monitoring at 6 months is justified to detect further increases that may warrant treatment adjustment between 3 and 6 months.
Current screening strategies in the development of selective androgen receptor modulators (SARMs) favor the selection of SARMs that are anabolic on the skeletal muscle and that spare the prostate (31); however, erythrocytosis, the most frequent adverse event in androgen trials, has received inadequate attention (2) . Although increase in hemoglobin might be beneficial in older men with anemia, the long-term health consequences of erythrocytosis are unknown. In epidemiological studies, high hematocrits are associated with increased risk of cerebrovascular disease and mortality (32) . Clinical trials of erythropoietin in patients with end-stage renal disease suggest that higher hematocrit targets may be associated with greater frequency of cardiovascular events and mortality than lower targets (33, 34) . A similar systematic investigation of optimal hematocrit targets in androgen-deficient men receiving testosterone therapy is desirable. Also, further refinements of the strategies for screening of SARMs are needed to facilitate selection of molecules that have minimal effect on erythropoiesis.
